Article
Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.
Cell reports - 6 Jul 2021
Dodagatta-Marri Eswari, Ma Hsiao-Yen, Liang Benjia, Li John, Meyer Dominique S, Chen Szu-Ying, Sun Kai-Hui, Ren Xin, Zivak Bahar, Rosenblum Michael D, Headley Mark B, Pinzas Lauren, Reed Nilgun I, Del Cid Joselyn S, Hann Byron C, Yang Sharon, Giddabasappa Anand, Noorbehesht Kavon, Yang Bing, Dal Porto Joseph, Tsukui Tatsuya, Niessen Kyle, Atakilit Amha, Akhurst Rosemary J, Sheppard Dean
Abstract excerpt
αvβ8 integrin, a key activator of transforming growth factor β (TGF-β), inhibits anti-tumor immunity. We show that a potent blocking monoclonal antibody against αvβ8 (ADWA-11) causes growth suppression or complete regression in syngeneic models of squamous cell carcinoma, mammary cancer, colon cancer, and prostate cancer, especially when combined with other immunomodulators or radiotherapy. αvβ8 is expressed at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.